New Horizon Health (FRA:6YZ) Ending Cash Position: €188.1 Mil (As of Jun. 2023)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:6YZ New Horizon Health Ltd FRA:6YZ
35 GF Score
Price €1.62
View Full Analysis

What is New Horizon Health Ending Cash Position?

New Horizon Health FRA:6YZ 35 Ending Cash Position is €188.1 Mil as of Jun. 2023. GuruFocus rates FRA:6YZ with a GF Score™ of 35/100.

New Horizon Health's Ending Cash Position for the quarter that ended in Jun. 2023 was €188.1 Mil.

New Horizon Health's quarterly Ending Cash Position declined from Jun. 2022 (€166.8 Mil) to Dec. 2022 (€153.2 Mil) but then increased from Dec. 2022 (€153.2 Mil) to Jun. 2023 (€188.1 Mil).

New Horizon Health's annual Ending Cash Position increased from Dec. 2020 (€56.8 Mil) to Dec. 2021 (€95.4 Mil) and increased from Dec. 2021 (€95.4 Mil) to Dec. 2022 (€153.2 Mil).

New Horizon Health Ending Cash Position Related Terms

New Horizon Health Ending Cash Position Historical Data

* Premium members only.

The historical data trend for New Horizon Health's Ending Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

New Horizon Health Ending Cash Position Chart

New Horizon Health Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22
Ending Cash Position
9.79 44.46 56.79 95.43 153.19

New Horizon Health Quarterly Data
Dec18 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23
Ending Cash Position Get a 7-Day Free Trial Premium Member Only 112.16 95.43 166.79 153.19 188.06
FRA:6YZ
35GF Score
New Horizon Health Ltd FRA:6YZ
Ending Cash Position is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

New Horizon Health Ending Cash Position Calculation

Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. It is equal to the Beginning Cash Position plus the Net Change in Cash.

New Horizon Health's Ending Cash Position for the fiscal year that ended in Dec. 2022 is calculated as

Ending Cash Position= Beginning Cash Position+Net Change in Cash
=92.998+60.195
=153.2

New Horizon Health's Ending Cash Position for the quarter that ended in Jun. 2023 is calculated as

Ending Cash Position=Beginning Cash Position+Net Change in Cash
=145.818+42.24
=188.1

Frequently Asked Questions Learn more about Ending Cash Position →
What does a Ending Cash Position of €188.1 Mil mean?
New Horizon Health (FRA:6YZ) has a Ending Cash Position of €188.1 Mil as of Jun. 2023. Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. View historical data on New Horizon Health and its competitors.
Is New Horizon Health's Ending Cash Position too high?
New Horizon Health's current Ending Cash Position is €188.1 Mil. Overall, New Horizon Health has a GF Score™ of 35/100, reflecting its overall financial health beyond just this single metric.
How does New Horizon Health's Ending Cash Position compare to ABT and SYK?
New Horizon Health's Ending Cash Position of €188.1 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Ending Cash Position for a Medical Devices & Instruments company?
A good Ending Cash Position depends on the Medical Devices & Instruments industry context. However, Ending Cash Position should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Ending Cash Position mean?
A high Ending Cash Position can signal that a stock is expensive relative to its fundamentals. Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. View historical data on New Horizon Health and its competitors. New Horizon Health's current Ending Cash Position is €188.1 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is New Horizon Health stock overvalued right now?
New Horizon Health (FRA:6YZ) has a current Ending Cash Position of €188.1 Mil. The current Ending Cash Position is €188.1 Mil. New Horizon Health's overall GF Score™ is 35/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Ending Cash Position calculated?
Ending Cash Position is calculated from a company's financial statements. For New Horizon Health (FRA:6YZ), the current Ending Cash Position is €188.1 Mil as of Jun. 2023. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

New Horizon Health Business Description

Address 400 Jiang’er Road, 13th Floor, T1 Building, Binjiang District, Zhejiang, Hangzhou, CHN, 310052
New Horizon Health Ltd is engaged in early cancer screening and in-home testing in China. The company has an early detection and cancer screening-focused pipeline of five products and product candidates with an emphasis on colorectal cancer screening. The company focuses on cancer prevention and cure through screening and early detection. It generates maximum revenue from ColoClear and Pupu Tube products.
35GF Score

Get the complete analysis for FRA:6YZ

Ending Cash Position is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€1.62
Price